Format

Send to

Choose Destination
  • Filters activated: Field: Title Word. Clear all
Mol Ther. 2017 May 3;25(5):1095-1106. doi: 10.1016/j.ymthe.2017.03.027. Epub 2017 Apr 4.

Cardiovascular Gene Therapy: Past, Present, and Future.

Author information

1
A.I. Virtanen Institute, University of Eastern Finland, Yliopistonranta 1, 70211 Kuopio, Finland; Heart Center and Gene Therapy Unit, Kuopio University Hospital, PO Box 100, 70029 KYS Kuopio, Finland. Electronic address: seppo.ylaherttuala@uef.fi.
2
Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.

Abstract

Cardiovascular diseases remain a large global health problem. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs. Among potential targets for gene therapy are severe cardiac and peripheral ischemia, heart failure, vein graft failure, and some forms of dyslipidemias. The first approved gene therapy in the Western world was indicated for lipoprotein lipase deficiency, which causes high plasma triglyceride levels. With improved gene delivery methods and more efficient vectors, together with interventional transgene strategies aligned for a better understanding of the pathophysiology of these diseases, new approaches are currently tested for safety and efficacy in clinical trials. In this article, we integrate a historical perspective with recent advances that will likely affect clinical development in this research area.

KEYWORDS:

cardiovascular gene therapy; clinical trials; endpoints; heart failure; hyperlipidemias; ischemia; trial design

PMID:
28389321
PMCID:
PMC5417840
DOI:
10.1016/j.ymthe.2017.03.027
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center